

Dirk Strumberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/982903/publications.pdf>

Version: 2024-02-01

63
papers

5,283
citations

159585

30
h-index

128289

60
g-index

65
all docs

65
docs citations

65
times ranked

6407
citing authors

#	ARTICLE	IF	CITATIONS
1	Intraperitoneale intraoperative Chemotherapie (HIPEC/PIPAC). Springer Reference Medizin, 2021, , 1-13.	0.0	0
2	Enhanced antitumoral activity of TLR7 agonists via activation of human endogenous retroviruses by HDAC inhibitors. Communications Biology, 2021, 4, 276.	4.4	16
3	Intraperitoneale intraoperative Chemotherapie (HIPEC/PIPAC). Springer Reference Medizin, 2021, , 1-13.	0.0	0
4	Safety, Efficacy and Pharmacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pancreatic Adenocarcinoma. A Randomized Phase Ib/Ila Study. Cancers, 2020, 12, 3130.	3.7	34
5	Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC) Tj ETQq1 1 0.784314 rgBT /Overlook Medical Oncology, 2019, 11, 175883591984640.	3.2	67
6	A Distinct Oncogenetic Multinucleated Cancer Cell Serves as a Source of Stemness and Tumor Heterogeneity. Cancer Research, 2018, 78, 2318-2331.	0.9	63
7	Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. British Journal of Cancer, 2017, 116, 1505-1512.	6.4	25
8	Cytotoxic stress induces transfer of mitochondria-associated human endogenous retroviral RNA and proteins between cancer cells. Oncotarget, 2017, 8, 95945-95964.	1.8	28
9	Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis. Journal of Gastrointestinal Surgery, 2016, 20, 367-373.	1.7	159
10	Preclinical evaluation of a diabody-based 177Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model. Cancer Letters, 2016, 381, 296-304.	7.2	3
11	A phase Ib/Ila study of combination therapy with gemcitabine and Atu027 in patients with locally advanced or metastatic pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, 385-385.	1.6	34
12	Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. European Journal of Cancer, 2015, 51, 942-949.	2.8	47
13	Therapeutic potential of antiviral drugs targeting chemorefractory colorectal adenocarcinoma cells overexpressing endogenous retroviral elements. Journal of Experimental and Clinical Cancer Research, 2015, 34, 81.	8.6	38
14	First-in-Human Phase I Study of the Liposomal RNA Interference Therapeutic Atu027 in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2014, 32, 4141-4148.	1.6	216
15	Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy. Annals of Surgical Oncology, 2014, 21, 553-559.	1.5	287
16	Atypical Cell Populations Associated with Acquired Resistance to Cytostatics and Cancer Stem Cell Features: The Role of Mitochondria in Nuclear Encapsulation. DNA and Cell Biology, 2014, 33, 749-774.	1.9	23
17	Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: Preliminary clinical experience. Gynecologic Oncology, 2014, 132, 307-311.	1.4	79
18	FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases " a CESAR phase II study including pharmacokinetic, biomarker, and imaging data. International Journal of Clinical Pharmacology and Therapeutics, 2014, 52, 642-652.	0.6	7

#	ARTICLE	IF	CITATIONS
19	Identification of compounds that selectively target highly chemotherapy refractory neuroblastoma cancer stem cells. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2014, 52, 787-801.	0.6	9
20	A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Aflibercept in Cancer Patients Treated With Docetaxel. <i>Journal of Cardiovascular Pharmacology</i> , 2013, 61, 495-504.	1.9	4
21	Flavonoids isolated from Caribbean propolis show cytotoxic activity in human cancer cell lines. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2013, 51, 51-53.	0.6	7
22	Multi-targeted polycyclic polyprenylated acylphloroglucinols are major constituents of Cuban propolis and contributors to its anticancer activity. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2013, 51, 54-55.	0.6	3
23	Sarcomatoid non-small cell lung cancer responding to sunitinib. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2013, 51, 87-88.	0.6	1
24	Efficacy and safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in women with recurrent gynaecological cancer and peritoneal carcinomatosis. <i>Journal of Clinical Oncology</i> , 2013, 31, e16523-e16523.	1.6	0
25	Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours. <i>Investigational New Drugs</i> , 2012, 30, 1962-1971.	2.6	16
26	Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBC 44): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 135-144.	10.7	425
27	7-epi-nemorosone from <i>Clusia rosea</i> induces apoptosis, androgen receptor down-regulation and dysregulation of PSA levels in LNCaP prostate carcinoma cells. <i>Phytomedicine</i> , 2012, 19, 1298-1306.	5.3	16
28	Sorafenib for the treatment of renal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 407-419.	1.8	25
29	Regorafenib for cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 879-889.	4.1	124
30	Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. <i>Investigational New Drugs</i> , 2012, 30, 1138-1143.	2.6	60
31	Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study) Tj ETQq1 1 0.784314 rgBT /Over 2.6 13	2.6	13
32	Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 753-761.	2.3	4
33	Antimetastatic activity of Atu027, a liposomal small interfering RNA formulation, targeting protein kinase N3 (PKN3): Final results of a phase I study in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2012, 30, e13597-e13597.	1.6	3
34	Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 72-73.	0.6	2
35	Angioimmunoblastic T-cell lymphoma, combined with antiphospholipid syndrome and autoimmune thrombocytopenia (Case Report). <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 74-75.	0.6	2
36	Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 76-78.	0.6	126

#	ARTICLE	IF	CITATIONS
37	Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer. <i>Vascular Cell</i> , 2011, 3, 16.	0.2	11
38	Observation of de Novo Bladder Dysfunction under Treatment with Her2-neu Antibodies. <i>Urologia Internationalis</i> , 2011, 86, 80-84.	1.3	3
39	Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 1389-1400.	2.5	22
40	Patient-based strategy for systemic treatment of metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 585-596.	2.4	20
41	Efficacy of Sunitinib and Sorafenib in Non-“Clear Cell Renal Cell Carcinoma: Results From Expanded Access Studies. <i>Journal of Clinical Oncology</i> , 2008, 26, 3469-3471.	1.6	9
42	Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors. <i>Oncologist</i> , 2007, 12, 426-437.	3.7	386
43	Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. <i>Cancer</i> , 2007, 109, 33-40.	4.1	60
44	Multicenter Phase II Trial of S-1 Plus Cisplatin in Patients With Untreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 663-667.	1.6	88
45	Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. <i>Melanoma Research</i> , 2005, 15, 205-207.	1.2	43
46	The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. <i>Anti-Cancer Drugs</i> , 2005, 16, 129-136.	1.4	42
47	Raf Kinase Inhibitors in Oncology. <i>Oncology Research and Treatment</i> , 2005, 28, 101-107.	1.2	31
48	Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 965-972.	1.6	830
49	Results of a Phase I Trial of Sorafenib (BAY 43-9006) in Combination with Oxaliplatin in Patients with Refractory Solid Tumors, Including Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2005, 5, 188-196.	2.3	107
50	Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. <i>Drugs of Today</i> , 2005, 41, 773.	1.1	173
51	A Mutation in Escherichia coli DNA Gyrase Conferring Quinolone Resistance Results in Sensitivity to Drugs Targeting Eukaryotic Topoisomerase II. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4495-4504.	3.2	32
52	Importance of the Fourth Alpha-Helix within the CAP Homology Domain of Type II Topoisomerase for DNA Cleavage Site Recognition and Quinolone Action. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 2735-2746.	3.2	13
53	Metal-Dependent Inhibition of HIV-1 Integrase. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 5661-5670.	6.4	83
54	Etoposide Metabolites Enhance DNA Topoisomerase II Cleavage near Leukemia-Associated MLL Translocation Breakpoints. <i>Biochemistry</i> , 2001, 40, 1159-1170.	2.5	79

#	ARTICLE	IF	CITATIONS
55	Conversion of Topoisomerase I Cleavage Complexes on the Leading Strand of Ribosomal DNA into 5â€²-Phosphorylated DNA Double-Strand Breaks by Replication Runoff. <i>Molecular and Cellular Biology</i> , 2000, 20, 3977-3987.	2.3	314
56	Synthesis of New Indeno[1,2-c]isoquinolines:â€” Cytotoxic Non-Camptothecin Topoisomerase I Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 3688-3698.	6.4	154
57	Mutation of a Conserved Serine Residue in a Quinolone-resistant Type II Topoisomerase Alters the Enzyme-DNA and Drug Interactions. <i>Journal of Biological Chemistry</i> , 1999, 274, 7292-7301.	3.4	19
58	Molecular Analysis of Yeast and Human Type II Topoisomerases. <i>Journal of Biological Chemistry</i> , 1999, 274, 28246-28255.	3.4	34
59	Synthesis of Cytotoxic Indenoisoquinoline Topoisomerase I Poisons. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 446-457.	6.4	122
60	Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1998, 1400, 83-106.	2.4	476
61	In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells. <i>Nucleic Acids Research</i> , 1997, 25, 4111-4116.	14.5	25
62	Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil. <i>Anti-Cancer Drugs</i> , 1997, 8, 293-295.	1.4	7
63	Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. <i>Anti-Cancer Drugs</i> , 1996, 7, 415-421.	1.4	134